Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) today announced presentations on plecanatide and SP-333, its proprietary guanylate cyclase-C (GC-C) agonists in development for gastrointestinal (GI) disorders, will take place at two scientific meetings this month.
Plecanatide, Synergy’s lead GC-C agonist for chronic idiopathic constipation and irritable bowel syndrome with constipation, will be featured in two oral presentations at the United European Gastroenterology (UEG) Week being held October 12-16 in Berlin, Germany.
Updated pre-clinical data on SP-333, the company’s next-generation GC-C agonist being studied for opioid-induced constipation and inflammatory bowel disease, will be featured in two poster presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting being held October 11-16 in San Diego, California.
Plecanatide Oral Presentations - UEG 2013Abstract: Acceleration of Time to First Bowel Movement in Chronic Idiopathic Constipation (CIC) Patients Receiving Plecanatide in a Large, Multicenter, Dose-Ranging StudyDate & Time: Tuesday, October 15 th, 8:42am – 8:54amAbstract Number: OP155Presenting Author: Ronald P. Fogel, M.D. (Digestive Health Centers of Michigan) Abstract: Plecanatide Produces a Diarrhea Plateau Effect in Chronic Idiopathic Constipation (CIC) PatientsDate & Time: Tuesday, October 15 th, 10:18am – 10:30amAbstract Number: OP163Presenting Author: Ronald P. Fogel, M.D. (Digestive Health Centers of Michigan) SP-333 Poster Presentations – ACG 2013 Abstract: Oral Treatment with SP-333, an Agonist of Guanylate Cyclase-C, Dramatically Ameliorates Morphine-Induced Bowel Dysfunction in RatsDate & Time: Tuesday, October 15 th, 10:30am – 4:00pmPoster Number: P1091Presenting Author: Kunwar Shailubhai, Ph.D., M.B.A.Note: Recipient of, “ACG’s 2013 Presidential Poster Award.” Posters receiving this award accumulated scores in the top five percent of the posters submitted for the ACG Annual Meeting in San Diego, CA. Abstract: SP-333, a Guanylate Cyclase-C Agonist, Inhibits NF-kB Signaling and Modulates Related Genes and miRNAs Implicated in GI Inflammation and CarcinogenesisDate & Time: Monday, October 14 th, 10:30am – 4:00pmPoster Number: P1049Presenting Author: Kunwar Shailubhai, Ph.D., M.B.A. About Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders. Synergy's lead proprietary drug candidate, plecanatide, is a synthetic analog of the human GI hormone, uroguanylin, and functions by activating the guanylate cyclase-C (GC-C) receptor on epithelial cells of the GI tract. In early 2013, Synergy announced positive results from a large multicenter trial of plecanatide in patients with chronic idiopathic constipation (CIC) and recently completed an end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA) covering the registration program for plecanatide to treat CIC. The company plans to initiate the phase 3 registration trial for plecanatide in CIC this quarter. Synergy is also developing plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C), recently announcing that it had reached the halfway mark for total enrollment in a plecanatide phase 2b clinical trial in patients with IBS-C. Synergy’s second GC-C agonist, SP-333, is in clinical development to treat opioid-induced constipation and inflammatory bowel disease. SP-333 has completed a phase I study in healthy volunteers and will enter phase 2 trials for OIC in the fourth quarter of 2013. More information is available at www.synergypharma.com .